Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma. (Q52649833)

From Wikidata

Jump to navigation Jump to search

scientific article published on 2 March 2018

Language	Label	Description	Also known as
English	Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.	scientific article published on 2 March 2018

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

based on heuristic

inferred from title

metastatic melanoma

1 reference

based on heuristic

inferred from title

Miles C Andrews

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jessica Da Gama Duarte

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Katherine Woods

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

author name string

Sagun Parakh

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Anupama Pasam

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Candani Tutuka

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Simone Ostrouska

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Jonathan M Blackburn

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Andreas Behren

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

publication date

2 March 2018

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Frontiers in Immunology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

411

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Advances in the development of human protein microarrays.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Is autoimmunity the Achilles' heel of cancer immunotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Targeted agents and immunotherapies: optimizing outcomes in melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Augmentation of Autoantibodies by Helicobacter pylori in Parkinson's Disease Patients May Be Linked to Greater Severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Immune escape mechanisms as a guide for cancer immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Chronic humoral rejection of human kidney allografts associates with broad autoantibody responses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Cancer/testis antigens, gametogenesis and cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Immunological factors which influence response to immunotherapy in malignant melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Complications of BCG immunotherapy in patients with cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Active specific immunotherapy in malignant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Prospective comparison of intralesional and multipuncture BCG in recurrent intradermal melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

22 May 2018

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5840202

13 August 2018

BCG Immunotherapy as a Systemic Adjunct to Surgery in Malignant Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BCG immunotherapy of malignant melanoma: summary of a seven-year experience

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of malignant melanoma by intratumoral injection of BCG

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of intravesical bacillus calmette-guerin (BCG) on carcinomain situ of the bladder

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Active immunotherapy by reinduction with a polyvalent allogeneic cell vaccine correlates with improved survival in recurrent metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of patients with progressive unresectable metastatic melanoma with a heterologous polyvalent melanoma whole cell vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/29552014

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.3389/FIMMU.2018.00411

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29552014%20AND%20SRC:MED&resulttype=core&format=json

20 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q52649833&oldid=1478421571"